HC Wainwright Analysts Give pSivida (PSDV) a $5.00 Price Target
Several other research firms have also recently commented on PSDV. B. Riley set a $5.00 target price on shares of pSivida and gave the company a buy rating in a research note on Monday, December 4th. Laidlaw started coverage on shares of pSivida in a research note on Wednesday, November 8th. They set a buy rating and a $5.00 target price for the company. Northland Securities reiterated a buy rating and set a $10.00 target price on shares of pSivida in a research note on Monday, December 11th. Finally, ValuEngine cut shares of pSivida from a sell rating to a strong sell rating in a research note on Friday, December 1st. One investment analyst has rated the stock with a sell rating and seven have issued a buy rating to the company. The company currently has an average rating of Buy and a consensus price target of $7.57.
Shares of pSivida (NASDAQ:PSDV) opened at $1.13 on Friday. pSivida has a one year low of $1.02 and a one year high of $2.45.
A hedge fund recently bought a new stake in pSivida stock. OxFORD Asset Management LLP purchased a new stake in pSivida Corp. (NASDAQ:PSDV) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 69,004 shares of the company’s stock, valued at approximately $118,000. OxFORD Asset Management LLP owned 0.18% of pSivida at the end of the most recent reporting period. 9.70% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION WARNING: “HC Wainwright Analysts Give pSivida (PSDV) a $5.00 Price Target” was reported by Watch List News and is the property of of Watch List News. If you are reading this story on another publication, it was stolen and republished in violation of international copyright legislation. The correct version of this story can be viewed at https://www.watchlistnews.com/hc-wainwright-analysts-give-psivida-psdv-a-5-00-price-target/1770912.html.
pSivida Corp. develops drug delivery products primarily for the treatment of chronic eye diseases. The Company operates through the biotechnology sector segment. The Company has developed three products for treatment of back-of-the-eye diseases, which include Medidur for posterior segment uveitis, its lead product candidate that is in pivotal Phase III clinical trials; ILUVIEN for diabetic macular edema (DME), its lead licensed product that is sold in the United States and European Union (EU) countries, and Retisert.
Receive News & Ratings for pSivida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for pSivida and related companies with MarketBeat.com's FREE daily email newsletter.